HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Ron Lanton, partner, Lanton Law, explains why evolving federal guidance and new technologies are pushing clinical operations teams to strengthen oversight and safeguard the credibility of clinical ...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 ...

Autonomix Medical (Nasdaq:AMIX) announced today that it advanced its proprietary sensing catheter through a final design ...

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption ("IDE"), and if ap ...

GCP compliance spans multiple parties; the article reviews their duties and proposes joint governance. By丨 Yongbin GE, ...

Anxiety symptoms among U.S. adults, even during the COVID-19 pandemic, appear to have remained stable, according to a massive ...

Discover Veru Inc.'s Q3 2025 earnings insights, including Phase III enobosarm trial updates, FDA feedback, and nondilutive funding plans for ...

Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some ...

It is vital that clinical trials for patients with cancer shift to a more representative approach to accurately reflect ...

Research and development expenses rose 68.8% year-over-year in Q2 2025, reflecting ongoing clinical trial spending, while revenue remained at zero. Protara ended the quarter with $145.6 million in ...